Home / Intelligence / Case Studies / Assessment of the Impact of National Guidelines on Uptake of a Biomarker Among HCPs and Payers
Trinity designed staggered quantitative research to assess the impact of national guidelines on uptake of a biomarker among HCPs and payers.
Geographic Scope: 
Client Situation
The client wanted to understand the impact of national physician society guidelines on uptake / acceptance of an innovative biomarker based on developed patient vignettes, and expectations for updates to payer diagnostic testing polices.
Trinity’s Solution
Trinity conducted qualitative research, fielding a survey with physicians and payers, to determine current physician utilization and payer coverage of biomarker diagnostic test and track evolution in payer policies and physician utilization with Wave II of the survey 6 – 12 months later.
Deliverables
- Interim findings of current physician utilization and payer coverage of the biomarker diagnostic test
- Final deliverable presenting the impact of the guidance on physicians and payers and providing recommendations to improve perception of the biomarker
Project Outcomes & Impact
Research findings helped the brand team to understand how the disease landscape will evolve as availability and adoption of the biomarker expands in the market, and then track this evolution on a longitudinal basis.
Related Intelligence
Webinars
Annual State of Global Market Access Webinar
Available On Demand
Trinity Life Sciences is pleased to release our highly anticipated white paper, the Annual State of Global Market Access. This year’s white paper focuses on six key global market access trends and provides payer perspectives on these trends. We explore the consequences of new therapeutic advances and policies aiming to control costs globally and the […]
Watch Now
Blog
Closing the Gap: Reflections on the 2023 Milken Institute Future of Health Summit
Introduction The Trinity team recently attended the Milken Institute’s 2023 Future of Health Summit in Washington, DC. Its theme was “Closing the Gap” in healthcare – as chronic disease becomes more prevalent worldwide and the average life expectancy in the US declines to its lowest level since the early 1990’s, what can be done? The […]
Read More
Blog
The Implementation Game: The Inflation Reduction Act Medicare Drug Price Negotiation Program Guidance
Trinity’s Take Introduction Since the Inflation Reduction Act (IRA) was signed into law in August 2022, biopharma stakeholders have noted the high likelihood of the legislation being challenged in court alongside many questions about how some of the new CMS programs would function. The Medicare Drug Price Negotiation Program is one IRA program expected to […]
Read More